Physician profile
Karla Alba
NPI 1184079485
$1,201.20
in general payments reported to CMS, 2019-2025
13 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $137 · 2024: $478 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $401.91 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $199.60 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $177.55 | 2024-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $107.75 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $68.96 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $62.21 | 2024-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $51.63 | 2024-2025 | Contrave |
| Abbott Laboratories | $33.93 | 2024-2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $33.51 | 2025 | Heplisav-B |
| Pfizer INC. | $17.26 | 2024 | |
| Phadia US INC. | $17.07 | 2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.78 | 2024 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Alba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.